Castleview Partners LLC Acquires 43,730 Shares of Bristol-Myers Squibb (NYSE:BMY)

Castleview Partners LLC raised its holdings in Bristol-Myers Squibb (NYSE:BMY) by 765.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 49,441 shares of the biopharmaceutical company’s stock after acquiring an additional 43,730 shares during the quarter. Bristol-Myers Squibb comprises 1.4% of Castleview Partners LLC’s portfolio, making the stock its 11th largest position. Castleview Partners LLC’s holdings in Bristol-Myers Squibb were worth $2,558,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BMY. ESL Trust Services LLC acquired a new stake in shares of Bristol-Myers Squibb during the first quarter worth $27,000. LGT Financial Advisors LLC increased its stake in Bristol-Myers Squibb by 42.7% in the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 227 shares during the last quarter. ORG Wealth Partners LLC acquired a new stake in Bristol-Myers Squibb in the 3rd quarter valued at $34,000. MFA Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb in the 2nd quarter valued at $39,000. Finally, Beach Investment Counsel Inc. PA acquired a new stake in Bristol-Myers Squibb in the 2nd quarter valued at $42,000. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Trading Down 1.4 %

NYSE BMY traded down $0.73 during mid-day trading on Monday, reaching $52.49. 2,002,805 shares of the stock were exchanged, compared to its average volume of 14,689,503. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02. The stock has a market cap of $106.40 billion, a P/E ratio of -17.17, a P/E/G ratio of 13.75 and a beta of 0.46. The stock has a 50 day simple moving average of $50.36 and a 200-day simple moving average of $46.33. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $56.77.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.64 by $0.43. The business had revenue of $12.20 billion during the quarter, compared to analysts’ expectations of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The business’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the company posted $1.75 earnings per share. On average, analysts anticipate that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.57%. The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BMY. TD Cowen lifted their price target on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday, October 7th. UBS Group upped their price target on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday, October 9th. Barclays increased their target price on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a research report on Monday, October 7th. Cantor Fitzgerald restated a “neutral” rating and set a $50.00 target price on shares of Bristol-Myers Squibb in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research report on Tuesday, July 23rd. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $53.20.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.